Oxitropium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Oxitropium
Accession Number
DB12086
Type
Small Molecule
Groups
Investigational
Description

Oxitropium has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Oxitropium bromideSF4NW7NH7C30286-75-0LCELQERNWLBPSY-KHSTUMNDSA-M
Categories
UNII
8G15T83E6I
CAS number
99571-64-9
Weight
Average: 332.419
Monoisotopic: 332.185634741
Chemical Formula
C19H26NO4
InChI Key
NVOYVOBDTVTBDX-PMEUIYRNSA-N
InChI
InChI=1S/C19H26NO4/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12/h4-8,13-18,21H,3,9-11H2,1-2H3/q+1/t13-,14-,15-,16+,17-,18+,20?/m1/s1
IUPAC Name
(1R,2R,4S,5S,7S)-9-ethyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
SMILES
CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumOxitropium may increase the anticholinergic activities of Aclidinium.Approved
AgmatineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Agmatine.Experimental, Investigational
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Oxitropium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Oxitropium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxitropium.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Oxitropium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxitropium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxitropium.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxitropium.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxitropium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxitropium.Approved
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Oxitropium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Oxitropium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxitropium.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Oxitropium.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Oxitropium.Experimental
Botulinum Toxin Type AOxitropium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Oxitropium is combined with Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Brompheniramine.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Oxitropium is combined with Bupropion.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Oxitropium.Approved, Investigational, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Oxitropium is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Oxitropium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxitropium.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Oxitropium.Approved
CimetropiumOxitropium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Oxitropium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxitropium.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxitropium.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxitropium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxitropium.Withdrawn
DextromethorphanThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxitropium.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dihydromorphine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxitropium.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxitropium is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Distigmine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Oxitropium.Approved
DonepezilThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Donepezil.Approved
DoxylamineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxitropium is combined with DPDPE.Experimental
DronabinolOxitropium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Edrophonium.Approved
EluxadolineOxitropium may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Oxitropium.Experimental
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Oxitropium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxitropium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Oxitropium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxitropium.Approved
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Oxitropium.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Fluoxetine.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Oxitropium.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxitropium.Approved
Ginkgo bilobaThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
Glucagon recombinantOxitropium may increase the gastrointestinal motility reducing activities of Glucagon recombinant.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxitropium.Approved, Investigational
GlycopyrroniumOxitropium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Oxitropium is combined with Heroin.Approved, Illicit, Investigational
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxitropium.Approved
Huperzine AThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxitropium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxitropium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxitropium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Oxitropium.Approved
IpidacrineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Ipratropium.Approved
IsoflurophateThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Oxitropium.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Ketobemidone.Approved, Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Oxitropium.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Lamotrigine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxitropium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Oxitropium is combined with Lofentanil.Illicit
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Oxitropium.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Oxitropium.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxitropium.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Oxitropium.Approved, Investigational, Vet Approved
MalathionThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxitropium.Approved, Investigational
MefloquineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Mefloquine.Approved, Investigational
MemantineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxitropium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxitropium.Approved, Investigational
MethscopolamineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Methscopolamine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Oxitropium.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Oxitropium is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxitropium.Approved
MetoclopramideThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Oxitropium.Approved
MianserinMianserin may increase the anticholinergic activities of Oxitropium.Approved, Investigational
MinaprineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxitropium.Approved, Vet Approved
MirabegronThe risk or severity of adverse effects can be increased when Oxitropium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Morphine.Approved, Investigational
NabiloneOxitropium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicardipineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxitropium.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Oxitropium.Experimental, Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxitropium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxitropium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxitropium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxitropium.Approved
ParaoxonThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Paraoxon.Experimental
ParoxetineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxitropium.Approved
PethidineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Oxitropium.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Oxitropium is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Physostigmine.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxitropium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxitropium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Oxitropium is combined with Piritramide.Approved, Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Oxitropium.Approved
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Oxitropium is combined with Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Oxitropium.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxitropium.Approved
PromethazineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Promethazine.Approved, Investigational
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxitropium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxitropium.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Quetiapine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Oxitropium.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxitropium.Approved, Investigational
RamosetronOxitropium may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Oxitropium is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxitropium.Approved, Investigational
Secretin humanThe therapeutic efficacy of Human secretin can be decreased when used in combination with Oxitropium.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxitropium.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxitropium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Oxitropium is combined with Sufentanil.Approved, Investigational
SulpirideOxitropium may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TacrineThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Tilidine.Experimental
TiotropiumOxitropium may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxitropium.Approved, Investigational
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Oxitropium is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Oxitropium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxitropium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxitropium.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Trimebutine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxitropium.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Oxitropium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxitropium.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxitropium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxitropium.Approved
TyrothricinThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumOxitropium may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxitropium.Approved
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Oxitropium is combined with WIN 55212-2.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
6917866
PubChem Substance
347828392
ChemSpider
32698552
ChEBI
135418
ATC Codes
R03BB02 — Oxitropium bromide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPulmonary Disease, Chronic Obstructive2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00635 mg/mLALOGPS
logP0.13ALOGPS
logP-2.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity100.38 m3·mol-1ChemAxon
Polarizability35.3 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Epoxides / Dialkyl ethers
show 9 more
Substituents
Beta-hydroxy acid / Monocyclic benzene moiety / Morpholine / Oxazinane / Piperidine / N-alkylpyrrolidine / Benzenoid / Tetraalkylammonium salt / Pyrrolidine / Quaternary ammonium salt
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:19 / Updated on August 02, 2018 06:33